| Literature DB >> 29474905 |
Takayuki Hoshii1, Paolo Cifani2, Zhaohui Feng1, Chun-Hao Huang3, Richard Koche4, Chun-Wei Chen1, Christopher D Delaney1, Scott W Lowe5, Alex Kentsis2, Scott A Armstrong6.
Abstract
MLL/SET methyltransferases catalyze methylation of histone 3 lysine 4 and play critical roles in development and cancer. We assessed MLL/SET proteins and found that SETD1A is required for survival of acute myeloid leukemia (AML) cells. Mutagenesis studies and CRISPR-Cas9 domain screening show the enzymatic SET domain is not necessary for AML cell survival but that a newly identified region termed the "FLOS" (functional location on SETD1A) domain is indispensable. FLOS disruption suppresses DNA damage response genes and induces p53-dependent apoptosis. The FLOS domain acts as a cyclin-K-binding site that is required for chromosomal recruitment of cyclin K and for DNA-repair-associated gene expression in S phase. These data identify a connection between the chromatin regulator SETD1A and the DNA damage response that is independent of histone methylation and suggests that targeting SETD1A and cyclin K complexes may represent a therapeutic opportunity for AML and, potentially, for other cancers.Entities:
Keywords: DNA damage response; SETD1A; cyclin K; histone methyltransferase; leukemia; transcription
Mesh:
Substances:
Year: 2018 PMID: 29474905 PMCID: PMC6052445 DOI: 10.1016/j.cell.2018.01.032
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850